Nava Ferdowsi

Mar 31, 2024 | mja.com.au | Prudence A. Francis |Nava Ferdowsi |Luigi Zolio

Med J Aust 2024; 220 (6): . || doi: 10.5694/mja2.52237 Published online: 1 April 2024 A 64‐year‐old woman presented with non‐neutropenic fever and back pain one day after the first cycle of neoadjuvant chemotherapy (doxorubicin–cyclophosphamide) for locally advanced breast cancer. She had also received pegylated granulocyte colony stimulating factor (PEG‐GCSF) one day after chemotherapy to enable dose‐dense chemotherapy scheduling.

Mar 25, 2024 | acrjournals.onlinelibrary.wiley.com | Zoe Brown |Zoé Brown |Dylan Hansen |Wendy Stevens |Nava Ferdowsi

INTRODUCTION In 2015, the European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines recommended a multidimensional risk assessment tool to guide treatment decisions and prognostication in pulmonary arterial hypertension (PAH) (Table 1).1 The 2015 ESC risk assessment tool stratified prognostic variables according to cut points as having low, intermediate, or high risk of 1-year mortality.

May 13, 2023 | arthritis-research.biomedcentral.com | Jessica Fairley |Dylan Hansen |Laura Ross |Susanna Proudman |Joanne Sahhar |Gene-Siew Ngian | +9 more

ParticipantsParticipants were recruited from the ASCS, a multicentre Australian study of SSc. The ASCS has been approved by all Human Research Ethics Committees of participating sites. Written informed consent was obtained from all participants prior to the collection of any study data. This study is conducted in accordance with the Declaration of Helsinki.